Resources>Blog>Chinese Antibody Society (CAS) Annual Conference 2024 – Boston: Event Recap

Chinese Antibody Society (CAS) Annual Conference 2024 – Boston: Event Recap

Biointron 2024-05-12 Read time: 3 mins

CAS.jpg

The Chinese Antibody Society (CAS) Annual Conference 2024 was held in Boston, MA on May 11. The meeting was titled “Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories” and featured the latest advancements in therapeutic antibodies, in addition to innovative approaches in their discovery, development, and manufacturing. Several prominent speakers in the biopharmaceutical field gave talks throughout the day.

Biointron Summary Report:

1. Cancer Immunotherapy

  • The keynote speaker of the day was Dr. Gordon Freeman from the Dana-Farber Cancer Institute, who gave insights into different types of studies on cancer therapies, the PD-L1 pathway, and isolation of functional monoclonal antibodies from experimental vaccines.

  • Antibody-guided T-cell therapy as an alternative to CAR-T or TCR-T strategies.

  • Targeting the CD24/Siglec-10 axis is a potential cancer therapy strategy based on the findings of current preclinical studies and clinical trial outcomes.

2. Alzheimer’s Disease

  • Developing antibodies targeting LILRB2/TREM2 to affect regulation of TREM2 functions, as both both LILRB2 and TREM2 are expressed in human brain microglia, which plays crucial roles in Alzheimer’s disease development.

3. Bioinformatics

  • Understanding the grammar and semantics of protein language models is important to use them as tools for predicting and designing protein structure and function. They learn from diverse sequences across the evolutionary tree.

  • Quantifiication of the success of antibody therapeutics over history.

4. Antibody Engineering

  • Payload-linker and conjugation technologies for novel and superior ADCs.

  • Engineering complex antigens and major histocompatibility complexes and multi-pass transmembrane proteins.

  • Production of camel and shark VHH antibodies neutralizing SARS-CoV-2 and Lassa virus.

Chinese Antibody Society.jpg

Thank you to all who visited our booth at CAS! We had a fantastic time connecting with you and sharing how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.

Subscribe to our Blog
Recommended Articles
Where Big Pharma Is Partnering for Antibody Discovery in 2026

Antibody discovery and development remain strategic priorities for major pharmac……

Dec 31, 2025
Camelid VHH Antibodies: Unique Origin, Structure, and Functional Advantages

VHH antibodies are single-domain antibody fragments derived from the unique heav……

Dec 29, 2025
Antibody-Drug Conjugates: An Advancing Field

As of the end of 2025, 21 ADCs have been approved globally, with four new approv……

Dec 26, 2025
Therapeutic Antibodies at the Intersection of Immune Tolerance and Tumor Immunity: Targeting Dendritic Cells, Tregs, and the Microenvironment
Dec 22, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.